1Hegadoren KM, Baker GB, Bourin M: 3, 4-Methylenedioxy analogues of amphetamine : defining the risks to humans. Neurosci Biobehav Rev. 1999; 24: 539-553.
2Gudelsky GA, Nash JF: Carrier-mediated release of serotonin by 3, 4-methylenedioxymeth-amphetamine: implications for serotonin-dopamine interactions. J Neurochem. 1996; 66:243-249.
3Huether G, Zhou D, Riither E: Causes and consequences of the loss of serotonergic presynapese elicited by the consumption of 3, 4-methylenedioxyme thamphetamine ( MDMA, "ecstasy") and its congeners. J Neural Transm. 1997; 104: 771-794.
4Wareing M, Fish JE, Murphy PN: Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol. 2000; 91: 181-188.
5Gerra G, Zaimovic A, Ferri M, et al: Long-lasting effects of 3, 4-methylenedioxymethamphetamine ( ecstasy ) on serotonin system function in humans. Boil Psychiatry, 2000; 47: 127-136.
6Shea E, Granados R, Esteban B, et al: The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA('Ecstasy'). Neuropharmacology, 1998; 37: 919-926.
8McGregor IS, Gurtman CG, Morley KC, et al: Increased anxiety and "depressive" symptoms months after MDMA ( "ecstasy") in rats: drugs-induced hyperthermia dose not predict long-term outcomes. Psychopharmacology (Berl), 2003 ; 168(4) : 465-474.
9Gudelsky G, Yamamoto B, Nash JF: MDMA increases the extracellular concentration of 2, 3-dihydroxybenzoic acid in the striatum: evidence for increased hydroxyl radical formation.Soc Neuroci Abstr, 1994; 20: 343.
10Giovanni A, Liang L, hastings TG, et al: Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate : impact of methamphetamine. J Neurochem.1995; 64: 1819-1825.
